Telo Genomics Corp
Telo Genomics Corp., a molecular diagnostics company, engages in the development and commercialization of predictive technological products to personalize treatment plans for patients with specific conditions, primarily in Canada. The company's TeloView platform measures the 3D structure and spatial organization of telomeres to inform on genetic and molecular characteristics that are predictive o… Read more
Telo Genomics Corp (TDSGF) - Total Assets
Latest total assets as of September 2025: $606.90K USD
Based on the latest financial reports, Telo Genomics Corp (TDSGF) holds total assets worth $606.90K USD as of September 2025.
Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Telo Genomics Corp - Total Assets Trend (2015–2025)
This chart illustrates how Telo Genomics Corp’s total assets have evolved over time, based on quarterly financial data. Explore and compare other companies by total assets.
Telo Genomics Corp - Asset Composition Analysis
Current Asset Composition (June 2025)
Telo Genomics Corp's total assets of $606.90K consist of 97.9% current assets and 2.1% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 86.6% |
| Accounts Receivable | $26.54K | 2.9% |
| Inventory | $0.00 | 0.0% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $0.00 | 0.0% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2015–2025)
This chart illustrates how Telo Genomics Corp's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Telo Genomics Corp's current assets represent 97.9% of total assets in 2025, an increase from 48.8% in 2015.
- Cash Position: Cash and equivalents constituted 86.6% of total assets in 2025, up from 44.5% in 2015.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, a decrease from 50.0% in 2015.
- Asset Diversification: The largest asset category is accounts receivable at 2.9% of total assets.
Telo Genomics Corp Competitors by Total Assets
Key competitors of Telo Genomics Corp based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
ADCNF
OTCGREY:ADCNF
|
USA | $4.51 Billion |
|
Berry Genomics Co Ltd
SHE:000710
|
China | CN¥2.34 Billion |
|
Malaysian Genomics Resource
KLSE:0155
|
Malaysia | RM20.70 Million |
|
NSN Co. Ltd
KQ:031860
|
Korea | ₩60.96 Billion |
|
JOONGANG DNM Co.Ltd
KQ:051980
|
Korea | ₩121.79 Billion |
|
GeneMatrix Inc
KQ:109820
|
Korea | ₩28.03 Billion |
|
Genoray Co. Ltd
KQ:122310
|
Korea | ₩125.67 Billion |
|
Green Cross Lab Cell Corporation
KQ:144510
|
Korea | ₩565.79 Billion |
Telo Genomics Corp - Asset Efficiency Metrics
Asset efficiency metrics measure how effectively a company uses its assets to generate revenue and profits. These indicators help investors evaluate management's ability to deploy capital efficiently.
Asset Turnover Ratio
Measures how efficiently a company uses its assets to generate sales
Lower asset utilization - Telo Genomics Corp generates 0.00x its asset value in annual revenue.
Return on Assets (ROA)
Measures how efficiently a company uses its assets to generate profits
Negative ROA - Telo Genomics Corp is currently not profitable relative to its asset base.
Telo Genomics Corp - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 0.93 | 0.99 | 9.17 |
| Quick Ratio | 0.93 | 0.99 | 9.17 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $-45.05K | $ -4.08K | $ 1.54 Million |
Telo Genomics Corp - Advanced Valuation Insights
This section examines the relationship between Telo Genomics Corp's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 5.83 |
| Latest Market Cap to Assets Ratio | 4.17 |
| Asset Growth Rate (YoY) | -5.6% |
| Total Assets | $911.30K |
| Market Capitalization | $3.80 Million USD |
Valuation Analysis
Premium Asset Valuation: The market values Telo Genomics Corp's assets at a significant premium ( 4.17x), suggesting investors see substantial growth potential or unique competitive advantages.
Significant Asset Reduction: Telo Genomics Corp's assets decreased by 5.6% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for Telo Genomics Corp (2015–2025)
The table below shows the annual total assets of Telo Genomics Corp from 2015 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-06-30 | $911.30K | -5.63% |
| 2024-06-30 | $965.64K | -66.99% |
| 2023-06-30 | $2.93 Million | +3.26% |
| 2022-06-30 | $2.83 Million | -26.20% |
| 2021-06-30 | $3.84 Million | +228.51% |
| 2020-06-30 | $1.17 Million | +344.92% |
| 2019-06-30 | $262.67K | -38.85% |
| 2018-06-30 | $429.51K | -86.20% |
| 2017-06-30 | $3.11 Million | +246.16% |
| 2016-06-30 | $899.22K | +53.05% |
| 2015-06-30 | $587.52K | -- |